Catalym Gmbh
Clinical trials sponsored by Catalym Gmbh, explained in plain language.
-
New antibody combo shows promise for hard-to-treat cancers
Disease control OngoingThis study tests a new drug called CTL-002 (visugromab) given alone or with an approved immunotherapy for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can help control the cancer. About 263 adult…
Phase: PHASE1, PHASE2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated May 26, 2026 12:01 UTC
-
New drug combo aims to shrink bladder tumors before surgery
Disease control OngoingThis study tests whether adding the experimental drug visugromab to standard immunotherapy can help shrink muscle-invasive bladder cancer before surgery. About 31 adults who cannot or choose not to receive cisplatin chemotherapy will receive the combination before having their bl…
Phase: PHASE2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated May 22, 2026 13:53 UTC